Escherichia coli-derived virus-like particles in vaccine development

Abstract Recombinant virus-like particle-based vaccines are composed of viral structural proteins and mimic authentic native viruses but are devoid of viral genetic materials. They are the active components in highly safe and effective vaccines for the prevention of infectious diseases. Several expr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaofen Huang, Xin Wang, Jun Zhang, Ningshao Xia, Qinjian Zhao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2f5ce63bc4174acb969cb8228053d3b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f5ce63bc4174acb969cb8228053d3b9
record_format	dspace
spelling	oai:doaj.org-article:2f5ce63bc4174acb969cb8228053d3b92021-12-02T16:19:41ZEscherichia coli-derived virus-like particles in vaccine development10.1038/s41541-017-0006-82059-0105https://doaj.org/article/2f5ce63bc4174acb969cb8228053d3b92017-02-01T00:00:00Zhttps://doi.org/10.1038/s41541-017-0006-8https://doaj.org/toc/2059-0105Abstract Recombinant virus-like particle-based vaccines are composed of viral structural proteins and mimic authentic native viruses but are devoid of viral genetic materials. They are the active components in highly safe and effective vaccines for the prevention of infectious diseases. Several expression systems have been used for virus-like particle production, ranging from Escherichia coli to mammalian cell lines. The prokaryotic expression system, especially Escherichia coli, is the preferred expression host for producing vaccines for global use. Hecolin, the first licensed virus-like particle vaccine derived from Escherichia coli, has been demonstrated to possess good safety and high efficacy. In this review, we focus on Escherichia coli-derived virus-like particle based vaccines and vaccine candidates that are used for prevention (immunization against microbial pathogens) or disease treatment (directed against cancer or non-infectious diseases). The native-like spatial or higher-order structure is essential for the function of virus-like particles. Thus, the tool box for analyzing the key physicochemical, biochemical and functional attributes of purified virus-like particles will also be discussed. In summary, the Escherichia coli expression system has great potentials for producing a range of proteins with self-assembling properties to be used as vaccine antigens given the proper epitopes were preserved when compared to those in the native pathogens or disease-related target molecules.Xiaofen HuangXin WangJun ZhangNingshao XiaQinjian ZhaoNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 2, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xiaofen Huang Xin Wang Jun Zhang Ningshao Xia Qinjian Zhao Escherichia coli-derived virus-like particles in vaccine development
description	Abstract Recombinant virus-like particle-based vaccines are composed of viral structural proteins and mimic authentic native viruses but are devoid of viral genetic materials. They are the active components in highly safe and effective vaccines for the prevention of infectious diseases. Several expression systems have been used for virus-like particle production, ranging from Escherichia coli to mammalian cell lines. The prokaryotic expression system, especially Escherichia coli, is the preferred expression host for producing vaccines for global use. Hecolin, the first licensed virus-like particle vaccine derived from Escherichia coli, has been demonstrated to possess good safety and high efficacy. In this review, we focus on Escherichia coli-derived virus-like particle based vaccines and vaccine candidates that are used for prevention (immunization against microbial pathogens) or disease treatment (directed against cancer or non-infectious diseases). The native-like spatial or higher-order structure is essential for the function of virus-like particles. Thus, the tool box for analyzing the key physicochemical, biochemical and functional attributes of purified virus-like particles will also be discussed. In summary, the Escherichia coli expression system has great potentials for producing a range of proteins with self-assembling properties to be used as vaccine antigens given the proper epitopes were preserved when compared to those in the native pathogens or disease-related target molecules.
format	article
author	Xiaofen Huang Xin Wang Jun Zhang Ningshao Xia Qinjian Zhao
author_facet	Xiaofen Huang Xin Wang Jun Zhang Ningshao Xia Qinjian Zhao
author_sort	Xiaofen Huang
title	Escherichia coli-derived virus-like particles in vaccine development
title_short	Escherichia coli-derived virus-like particles in vaccine development
title_full	Escherichia coli-derived virus-like particles in vaccine development
title_fullStr	Escherichia coli-derived virus-like particles in vaccine development
title_full_unstemmed	Escherichia coli-derived virus-like particles in vaccine development
title_sort	escherichia coli-derived virus-like particles in vaccine development
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/2f5ce63bc4174acb969cb8228053d3b9
work_keys_str_mv	AT xiaofenhuang escherichiacoliderivedviruslikeparticlesinvaccinedevelopment AT xinwang escherichiacoliderivedviruslikeparticlesinvaccinedevelopment AT junzhang escherichiacoliderivedviruslikeparticlesinvaccinedevelopment AT ningshaoxia escherichiacoliderivedviruslikeparticlesinvaccinedevelopment AT qinjianzhao escherichiacoliderivedviruslikeparticlesinvaccinedevelopment
_version_	1718384161227538432

Escherichia coli-derived virus-like particles in vaccine development

Ejemplares similares